Fairview HK: Krystal is promising, but there are several possible hazards to be aware of

CENTRAL, Hong Kong - Nov. 8, 2022 - PRLog -- But it's been a wild trip and there might be more twists and turns ahead for KRYS in the next ten months. On the other side, there are several reasons why the biotech sector might continue to outperform the market.

KRYS is now a clinical-stage business focusing on uncommon dermatologic illnesses. However, it has lately moved a step closer to putting a product on the market. KRYS filed an application with the U.S. Patent and Trademark Office in June. Vyjuvek, a possible gene-editing treatment for dystrophic epidermolysis bullosa (DEB), has been approved by the Food and Drug Administration (FDA)

This uncommon disorder weakens the skin and makes it more vulnerable to injury. DEB is caused by a faulty gene and Vyjuvek treats the condition at the genetic level. In clinical studies, Vyjuvek showed promising outcomes. In a study of 31 DEB patients with Vyjuvek-treated wounds, 71% and 67% completed full wound healing three months and six months after therapy, respectively.

In comparison, just 20% of placebo-treated wounds obtained the same result after three months and 22% after six months. Furthermore, no serious adverse responses were recorded during the experiment, with only one moderate reaction. In other words, Vyjuvek appears to have a high level of safety and efficacy. Based on genetic predominance, there might be 9,000 DEB sufferers worldwide according to KRYS.

This includes around 3,000 in the United States and 3,000 in Europe. While this may not appear to be a large patient group, gene treatments are not recognized for being inexpensive. According to KRYS, the DEB market provides a more than $500 million global opportunity. During 2022, the business intends to file an application for Vyjuvek in Europe in the latter part of the year.

Although the therapeutic study data appears positive, Vyjuvek may face unexpected regulatory issues. It's also critical to think about KRYS's capacity to fund its activities. Smaller biotech companies are frequently plagued by significant financial constraints. KRYS is currently not profitable and does not earn any money. The gene-editing company had $269.3 million in cash and cash equivalents at the end of the first quarter, with an additional $165.3 million in short-term investments.

Fairview HK Limited is one of the foremost privately owned Asia-Pacific orientated, boutique wealth management firms in Hong Kong. We offer our services to a selected group of families, family offices, institutions and fund managers, you may visit our website https://fairviewhk.com/ or contact us via email.